查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1916496

全球前列腺癌治療市場：市場規模、份額、成長率、行業分析、按類型、應用和地區劃分的考慮因素以及未來預測（2026-2034）

Prostate Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

攝護腺癌治療市場成長因素

全球前列腺癌治療市場是腫瘤領域成長最快的細分市場之一，其成長主要受男性老化導致前列腺癌發病率上升以及標靶治療和精準醫療快速發展所驅動。預計到2025年，全球前列腺癌治療市場規模將達到251.2億美元。在診斷率不斷提高和先進療法廣泛應用的推動下，預計到2026年，前列腺癌市場規模將增長至343.5億美元，並在2034年進一步顯著擴大至1068.6億美元，在整個預測期內保持強勁的增長勢頭。

攝護腺癌主要影響老年男性，且大多數確診病例發生在65歲及以上的族群。提高公眾意識的宣傳活動、常規前列腺特異性抗原（PSA）篩檢以及醫療保健服務可近性的改善，都促進了診斷率的上升。因此，從荷爾蒙療法到先進的標靶療法和免疫療法，全球對有效治療方案的需求持續成長。

市場動態

推動市場擴張的關鍵因素是全球前列腺癌發生率的上升。根據世界癌症資料庫，前列腺癌仍然是男性最常見的惡性腫瘤之一。早期診斷推廣工作和宣傳活動，例如一年一度的世界前列腺癌宣傳活動，正在進一步推動治療方案的普及。

然而，市場也面臨諸多限制因素。荷爾蒙療法的抗藥性，尤其是去勢抵抗性前列腺癌的出現，會降低長期治療效果。此外，化療和荷爾蒙療法相關的副作用，例如疲勞、骨密度下降和代謝併發症，也會限制部分患者的治療順從性。

儘管存在這些挑戰，但強大的研發投入正在為市場開闢新的成長途徑。製藥公司正致力於研發聯合療法，將雄性激素受體抑制劑 (ARI) 與 PARP 抑制劑、放射性配體療法和雄性素剝奪療法 (ADT) 結合，以克服抗藥性並改善晚期疾病的治療效果。

市場趨勢

前列腺癌藥物市場最顯著的趨勢之一是向標靶治療和個人化醫療的轉變。針對攜帶特定基因突變（例如 BRCA1 和 BRCA2）的患者設計的治療方案正日益受到關注。放射性藥物和精準腫瘤藥物的核准數量不斷增加，正在重塑治療路徑，尤其是在轉移性去勢抗性前列腺癌領域。

此外，口服藥物製劑因其患者依從性更高、更容易長期疾病管理而日益普及，從而推動了市場份額的擴大。

依細分市場分析

依藥物類別劃分，雄性激素受體抑制劑佔據最大的市場份額。這是因為它們能夠抑制睪酮介導的癌症進展。預計到 2026 年，該細分市場將佔總市場的 70% 以上，這反映了其作為晚期疾病一線治療方案的地位。

按給藥途徑劃分，口服療法因其易用性和更高的依從性而佔據主導地位，而腸外療法在晚期和住院治療中仍然發揮著重要作用。

按治療類型劃分，荷爾蒙療法仍然是前列腺癌治療的基石，其次是標靶治療和免疫療法。轉移性去勢抵抗性前列腺癌細分市場在所有疾病狀態中佔據最大份額，這主要歸因於其高治療需求和不斷增加的核准療法。

區域展望

北美地區預計將在 2025 年引領全球前列腺癌治療市場，佔據 51.37% 的市場份額，這得益於其先進的醫療保健基礎設施、高診斷率以及對新型療法的快速應用。 2025年，區域市場價值為129億美元，預計2026年將成長至180.8億美元。

歐洲是第二大區域市場，其成長主要得益於疾病盛行率的上升以及對創新癌症療法的強有力的監管支持。亞太地區正在崛起為高成長區域，這得益於癌症發病率的上升、醫療保健覆蓋範圍的擴大以及全球和區域製藥公司之間的戰略聯盟。

這份前列腺癌治療市場報告對全球產業格局進行了全面深入的分析，重點在於2025年、2026年和2034年的市場規模、成長軌跡和競爭格局。本研究詳細分析了影響全球前列腺癌治療普及的關鍵參數，包括市場驅動因素、限制因素、機會、挑戰和新興趨勢。

本報告從多個細分類別對市場進行評估，包括藥物類別、給藥途徑、治療類型、疾病狀態和分銷管道，以深入了解需求模式和治療偏好。此外，報告還對北美、歐洲、亞太地區、拉丁美洲以及中東和非洲進行了全面的區域評估，揭示了各區域的市場規模、成長潛力和監管環境。

報告還包含廣泛的競爭格局分析，概述了主要製藥和生物製藥公司及其產品組合、戰略舉措、研發管線和近期監管批准情況。報告還分析了 COVID-19 的影響、標靶和個人化治療的進展以及向聯合療法的轉變，從而全面展現了市場演變。

儘管治療抗藥性、治療相關副作用和高昂成本等挑戰依然存在，但對聯合療法、放射性藥物和精準醫療的持續研究正在重塑治療模式。北美憑藉其強大的醫療保健基礎設施和對新型藥物的快速應用，繼續保持領先地位，而歐洲和亞太地區正在崛起為關鍵增長區域。總體而言，預計在報告涵蓋的2025年、2026年和2034年期間，前列腺癌治療市場仍將是全球癌症治療行業中至關重要且快速發展的細分市場。

目錄

第一章：引言

第二章：執行摘要

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 全球市場主要趨勢
  • 最新技術進展
  • 監理環境分析
  • 波特五力分析
  • 關稅對市場的影響

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇

第四章主要發現

  • 主要國家和地區的攝護腺癌盛行率（2025 年）
  • 主要公司在研產品分析
  • 替代療法概述
  • 市場主要新創企業
  • 主要公司新產品發布
  • 主要趨勢：併購、合作等
  • 新冠疫情對市場的影響

第五章 全球前列腺癌藥物市場分析：洞察與預測（2021-2034 年）

  • 市場分析、洞察與預測：依藥物類別劃分
    • 雄性激素受體抑制劑
    • 微管抑制劑
    • 促性腺激素釋放激素 (GnRH) 激動劑
    • 促性腺激素釋放激素 (GnRH) 受體拮抗劑
    • 其他
  • 市場分析、洞察與預測：依給藥途徑
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測：按療法
    • 化療
    • 荷爾蒙單藥治療
    • 標靶治療
    • 免疫治療
  • 市場分析、洞察與預測：按適應症
    • 轉移性去勢抵抗性攝護腺癌
    • 非轉移性去勢抵抗性攝護腺癌
  • 市場分析、洞察與預測：依通路通路
    • 醫院藥房
    • 藥局和零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：按地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美前列腺癌藥物市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲前列腺癌藥物市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 美國王國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 其他歐洲國家

第八章 亞太地區前列腺癌藥物市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 其他亞太地區

第九章 拉丁美洲前列腺癌藥物市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第十章 中部東非與非洲前列腺癌藥物市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 世界市場佔有率分析(2025年)
  • 企業簡介
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Johnson &Johnson Services, Inc.
    • Sanofi
    • Ferring Pharmaceuticals Inc.
    • Sumitomo Pharma Co., Ltd.(Myovant Sciences GmbH)
    • AbbVie Inc.
    • AstraZeneca
    • Tolmar, Inc.
    • Dendreon Pharmaceuticals LLC.
    • Bayer AG
Product Code: FBI112008

Growth Factors of prostate cancer therapeutics Market

The global prostate cancer therapeutics market represents one of the fastest-growing segments within the oncology landscape, driven by the rising incidence of prostate cancer among aging male populations and the rapid advancement of targeted and precision therapies. In 2025, the global prostate cancer therapeutics market was valued at USD 25.12 billion. With increasing diagnosis rates and wider adoption of advanced treatment modalities, the market is projected to grow to USD 34.35 billion in 2026 and further expand significantly to USD 106.86 billion by 2034, reflecting strong momentum throughout the forecast period.

Prostate cancer primarily affects older men, with a majority of diagnoses occurring in individuals aged 65 years and above. Rising awareness campaigns, routine prostate-specific antigen (PSA) screening, and improved access to healthcare services are contributing to higher diagnosis rates. As a result, demand for effective therapeutic options-ranging from hormone therapy to advanced targeted and immunotherapies-continues to accelerate globally.

Market Dynamics

A key driver supporting market expansion is the rising global prevalence of prostate cancer. According to global cancer databases, prostate cancer remains one of the most commonly diagnosed malignancies in men worldwide. Early diagnosis initiatives and awareness programs, such as annual global prostate cancer awareness campaigns, are further contributing to treatment adoption.

However, the market faces notable restraints. Resistance to hormone therapy, particularly the development of castration-resistant prostate cancer, reduces long-term treatment effectiveness. Additionally, adverse effects associated with chemotherapy and hormonal treatments-such as fatigue, bone density loss, and metabolic complications-can limit therapy continuation in some patients.

Despite these challenges, strong research and development investments are opening new growth avenues. Pharmaceutical companies are increasingly focusing on combination therapies, pairing androgen receptor inhibitors with PARP inhibitors, radioligand therapies, and androgen deprivation therapy to overcome resistance and improve outcomes in advanced disease stages.

Market Trends

One of the most prominent trends in the prostate cancer therapeutics market is the shift toward targeted and personalized medicine. Therapies designed for patients with specific genetic mutations, such as BRCA1 and BRCA2, are gaining traction. The increasing approval of radiopharmaceuticals and precision oncology drugs is reshaping treatment pathways, especially for metastatic castration-resistant prostate cancer.

Additionally, oral drug formulations are gaining preference due to better patient compliance and convenience in long-term disease management, contributing to their growing market share.

Segmentation Insights

By drug class, androgen receptor inhibitors account for the largest share of the market, supported by their effectiveness in blocking testosterone-driven cancer progression. In 2026, this segment is projected to hold over 70% of the total market share, reflecting its role as a first-line therapy in advanced cases.

By route of administration, oral therapies dominate due to ease of use and improved adherence, while parenteral therapies continue to play an important role in advanced and hospital-based treatment settings.

From a therapy perspective, hormonal therapy remains a cornerstone of prostate cancer management, followed by targeted therapy and immunotherapy. The metastatic castration-resistant prostate cancer segment represents the largest disease-state share, owing to its high treatment demand and increasing number of regulatory approvals.

Regional Outlook

North America dominated the global prostate cancer therapeutics market in 2025, accounting for 51.37% of total market share, supported by advanced healthcare infrastructure, high diagnosis rates, and rapid adoption of novel therapies. The regional market was valued at USD 12.9 billion in 2025 and increased to USD 18.08 billion in 2026.

Europe represents the second-largest regional market, driven by rising disease prevalence and strong regulatory support for innovative oncology drugs. Asia Pacific is emerging as a high-growth region, supported by increasing cancer incidence, expanding healthcare access, and strategic collaborations between global and regional pharmaceutical companies.

Competitive Landscape

The market is highly competitive, with leading pharmaceutical and biopharmaceutical companies actively investing in clinical trials, regulatory approvals, and strategic collaborations. Key players include Pfizer Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., AstraZeneca, AbbVie Inc., and Bayer AG. Recent years have seen a surge in pipeline activity, particularly in radioligand therapies and next-generation targeted treatments, reinforcing long-term market expansion prospects.

Report Coverage

The prostate cancer therapeutics market report provides a comprehensive and in-depth analysis of the global industry landscape, focusing on market size, growth trajectory, and competitive dynamics in line with the report years 2025, 2026, and 2034. The study covers detailed insights across key parameters, including market drivers, restraints, opportunities, challenges, and emerging trends influencing the adoption of prostate cancer treatments worldwide.

The report evaluates the market across multiple segmentation categories such as drug class, route of administration, therapy type, disease state, and distribution channel, offering a granular understanding of demand patterns and treatment preferences. In addition, it presents a thorough regional assessment covering North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, highlighting region-wise market size, growth potential, and regulatory environments.

Furthermore, the report includes an extensive competitive landscape analysis, profiling leading pharmaceutical and biopharmaceutical companies, their product portfolios, strategic initiatives, pipeline developments, and recent regulatory approvals. The impact of COVID-19, advances in targeted and personalized therapies, and the shift toward combination treatments are also analyzed to provide a holistic view of the market's evolution.

Conclusion

The global prostate cancer therapeutics market is positioned for robust and sustained growth, supported by the rising prevalence of prostate cancer, increasing diagnosis rates, and continuous advancements in oncology drug development. With a market valuation of USD 25.12 billion in 2025, the expansion to USD 34.35 billion in 2026 reflects accelerating adoption of advanced hormonal, targeted, and immunotherapies. The projected growth to USD 106.86 billion by 2034 underscores the long-term significance of innovation-driven treatment strategies in prostate cancer care.

While challenges such as therapy resistance, treatment-related side effects, and high costs remain, ongoing research into combination therapies, radiopharmaceuticals, and precision medicine is reshaping the treatment paradigm. North America continues to dominate due to strong healthcare infrastructure and rapid uptake of novel drugs, while Europe and Asia Pacific are emerging as key growth regions. Overall, aligned strictly with the report years 2025, 2026, and 2034, the prostate cancer therapeutics market is expected to remain a critical and rapidly evolving segment within the global oncology industry.

Segmentation By Drug Class

  • Androgen Receptor Inhibitors
  • Microtubule Inhibitors
  • Gonadotropin Releasing Hormone (GnRH) Agonist
  • Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Therapy

  • Chemotherapy
  • Hormonal Therapy
  • Targeted therapy
  • Immunotherapy

By Disease State

  • Metastatic Castration-Resistant Prostate Cancer
  • Non-Metastatic Castration-Resistant Prostate Cancer

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. Key Start-ups in the Market
  • 4.5. New Product Launches, by Key Players
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.7. Impact of COVID-19 on the Market

5. Global Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Androgen Receptor Inhibitors
    • 5.1.2. Microtubule Inhibitors
    • 5.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 5.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Therapy
    • 5.3.1. Chemotherapy
    • 5.3.2. Hormonal Therapy
    • 5.3.3. Targeted therapy
    • 5.3.4. Immunotherapy
  • 5.4. Market Analysis, Insights and Forecast - By Disease State
    • 5.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 5.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Drug Stores & Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Androgen Receptor Inhibitors
    • 6.1.2. Microtubule Inhibitors
    • 6.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 6.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Therapy
    • 6.3.1. Chemotherapy
    • 6.3.2. Hormonal Therapy
    • 6.3.3. Targeted therapy
    • 6.3.4. Immunotherapy
  • 6.4. Market Analysis, Insights and Forecast - By Disease State
    • 6.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 6.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Drug Stores & Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Androgen Receptor Inhibitors
    • 7.1.2. Microtubule Inhibitors
    • 7.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 7.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Therapy
    • 7.3.1. Chemotherapy
    • 7.3.2. Hormonal Therapy
    • 7.3.3. Targeted therapy
    • 7.3.4. Immunotherapy
  • 7.4. Market Analysis, Insights and Forecast - By Disease State
    • 7.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 7.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Drug Stores & Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. Germany
    • 7.6.2. U.K.
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Androgen Receptor Inhibitors
    • 8.1.2. Microtubule Inhibitors
    • 8.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 8.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Therapy
    • 8.3.1. Chemotherapy
    • 8.3.2. Hormonal Therapy
    • 8.3.3. Targeted therapy
    • 8.3.4. Immunotherapy
  • 8.4. Market Analysis, Insights and Forecast - By Disease State
    • 8.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 8.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Drug Stores & Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Androgen Receptor Inhibitors
    • 9.1.2. Microtubule Inhibitors
    • 9.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 9.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Therapy
    • 9.3.1. Chemotherapy
    • 9.3.2. Hormonal Therapy
    • 9.3.3. Targeted therapy
    • 9.3.4. Immunotherapy
  • 9.4. Market Analysis, Insights and Forecast - By Disease State
    • 9.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 9.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Drug Stores & Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Androgen Receptor Inhibitors
    • 10.1.2. Microtubule Inhibitors
    • 10.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 10.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Therapy
    • 10.3.1. Chemotherapy
    • 10.3.2. Hormonal Therapy
    • 10.3.3. Targeted therapy
    • 10.3.4. Immunotherapy
  • 10.4. Market Analysis, Insights and Forecast - By Disease State
    • 10.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 10.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Drug Stores & Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Astellas Pharma Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Ferring Pharmaceuticals Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. AbbVie Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. AstraZeneca
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Tolmar, Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Dendreon Pharmaceuticals LLC.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Bayer AG
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
  • Table 4: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 5: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 8: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
  • Table 10: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 11: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 14: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
  • Table 16: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 17: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 20: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 21: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
  • Table 22: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 23: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 26: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 27: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
  • Table 28: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 29: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 32: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 33: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
  • Table 34: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 35: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Prostate Cancer Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025 & 2034
  • Figure 5: Global Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025 & 2034
  • Figure 6: Global Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Prostate Cancer Therapeutics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 8: North America Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 9: North America Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 10: North America Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 11: North America Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 12: North America Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 13: North America Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 14: North America Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 15: North America Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
  • Figure 16: North America Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Prostate Cancer Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America Prostate Cancer Therapeutics Market Value Share (%), By Country, 2025
  • Figure 20: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 21: Europe Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 22: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 23: Europe Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 24: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 25: Europe Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 26: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 27: Europe Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
  • Figure 28: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 33: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 34: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 35: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 36: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion),by Therapy, 2025 & 2034
  • Figure 37: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 38: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 39: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
  • Figure 40: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 45: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 46: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 47: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 48: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 49: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 50: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 51: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
  • Figure 52: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 57: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 58: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 59: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 60: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 61: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 62: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 63: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
  • Figure 64: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Prostate Cancer Therapeutics Market Share (%), By Company, 2025